Results 31 to 40 of about 464,460 (389)

Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant.

open access: yesJAMA Internal Medicine, 2019
Importance Patients with atrial fibrillation (AF) who use a direct oral anticoagulant (DOAC) and request elective surgery or procedure present a common clinical situation yet perioperative management is uncertain. Objective To investigate the safety of
J. Douketis   +30 more
semanticscholar   +1 more source

Prediction Score for Anticoagulation Control Quality Among Older Adults

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundTime in the therapeutic range (TTR) is associated with the effectiveness and safety of vitamin K antagonist (VKA) therapy. To optimize prescribing of VKA, we aimed to develop and validate a prediction model for TTR in older adults taking VKA ...
Kueiyu Joshua Lin   +8 more
doaj   +1 more source

Anticoagulants for acute ischaemic stroke [PDF]

open access: yes, 2015
Peer reviewedPublisher ...
Counsell, Carl   +2 more
core   +1 more source

Trends in anticoagulant prescribing: a review of local policies in English primary care

open access: yesBMC Health Services Research, 2020
Background Oral anticoagulants are prescribed for stroke prophylaxis in patients with atrial fibrillation, which is the most common heart arrhythmia worldwide. The vitamin K antagonist (VKA) warfarin is a long-established anticoagulant.
Katherine H. Ho, M. van Hove, G. Leng
semanticscholar   +1 more source

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundThe nonvitamin K antagonist oral anticoagulants have recently become available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on real‐life patient experience, including bleeding risk, are lacking.
Morten Lamberts   +8 more
doaj   +1 more source

Anticoagulation in cirrhosis [PDF]

open access: yesLiver International, 2012
The Authors review and comment a recent publication by Senzolo et al.
VILLA, Erica, N. De Maria
openaire   +4 more sources

The Anticoagulant and Nonanticoagulant Properties of Heparin

open access: yesThrombosis and Haemostasis, 2020
Heparins represent one of the most frequently used pharmacotherapeutics. Discovered around 1926, routine clinical anticoagulant use of heparin was initiated only after the publication of several seminal papers in the early 1970s by the group of Kakkar ...
D. Beurskens   +5 more
semanticscholar   +1 more source

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundWe studied the concomitant use of single antiplatelet therapy (SAPT) on the efficacy and safety of the anti‐Xa agent edoxaban in patients with atrial fibrillation (AF). Methods and ResultsENGAGE AF‐TIMI 48 was a randomized trial that compared 2
Haiyan Xu   +9 more
doaj   +1 more source

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects

open access: yesFrontiers in Pharmacology, 2022
Background: Targeting factor XI (FXI) is a promising therapeutic strategy for the treatment and prevention of thrombosis without increasing the risk of bleeding. Here, we assessed the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SHR2285, a
Rui Chen   +7 more
doaj   +1 more source

Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration

open access: yesJournal of Thrombosis and Haemostasis, 2020
Coronavirus disease (COVID‐19) is associated with a high incidence of thrombosis and mortality despite standard anticoagulant thromboprophylaxis. There is equipoise regarding the optimal dose of anticoagulant intervention in hospitalized patients with ...
T. Tritschler   +33 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy